Mantle cell lymphoma (MCL) is aggressive, and relapsed/refractory disease has poor outcomes, but a novel approach involving an oral arsenic-based regimen may help improve treatment.

To evaluate the potential of this regimen, researchers conducted a study involving 39 patients with relapsed/refractory MCL, ineligible for high-dose chemotherapy and had received two prior regimens, were treated with a continuous oral regimen, comprising oral arsenic trioxide, chlorambucil and ascorbic acid.

READ FULL ARTICLE Curated publisher From Annals of Oncology